Fosfomycin disodium is under clinical development by Meitheal Pharmaceuticals and currently in Pre-Registration for Urinary Tract Infections. According to GlobalData, Pre-Registration drugs for Urinary Tract Infections have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Fosfomycin disodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fosfomycin disodium overview
Fosfomycin disodium is under development for the treatment of complicated urinary tract infections (cUTI), acute pyelonephritis, suspected infection or peri-operative prophylaxis in pediatrics, pediatric acute lymphoblastic leukemia and other unspecified infections. It is formulated as powder and administered through intravenous route. The drug candidate inhibits cell wall synthesis. The drug candidate is a broad-spectrum intravenous phosphonic acid derivative and the only member of the epoxide antibiotic class. The drug candidate inhibits the PG and thereby aid in the treatment of the condition. It was also under development for complicated intra-abdominal infections (cIAI), acute bacterial skin and skin structure infections(ABSSI) and hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP).
Meitheal Pharmaceuticals overview
Meitheal Pharmaceuticals, a subsidiary of Nanjing King-friend Biochemical Pharmaceutical Co Ltd, is a biopharmaceutical company engaged in the production and distribution of generic pharmaceutical products, biosimilars, biologics, and fertility medicines. The company is headquartered in Chicago, Illinois, the US.
For a complete picture of Fosfomycin disodium’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
